Ono Pharmaceutical (OPHLF) Expected to Announce Earnings on Friday

Ono Pharmaceutical (OTCMKTS:OPHLF) is anticipated to post its resultson Friday, July 31st. Analysts expect Ono Pharmaceutical to post earnings of $0.25 per share and revenue of $679.8910 million for the quarter.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS:OPHLF opened at $13.38 on Friday. The company has a market cap of $6.29 billion, a price-to-earnings ratio of 13.52 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. The firm has a 50 day simple moving average of $14.32 and a 200 day simple moving average of $14.73. Ono Pharmaceutical has a one year low of $10.27 and a one year high of $18.67.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Ono Pharmaceutical has an average rating of “Strong Buy”.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.